Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof

Patent metadata

Field	Value
Publication number	US-11517616-B2
Application number	US-201716343903-A
Country	US
Kind code	B2
Filing date	Oct 19, 2017
Priority date	Oct 23, 2016
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

First claim

The invention claimed is:

1. A composite polypeptide, which comprises a polypeptide of the following formula (1):
W-L1-Xn-Y  (1)

wherein W is an amino acid sequence comprising a part or the entirety of a virus structural protein as an immunogen of a vaccine against the virus; L1 is a first linker sequence having 0 to 100 amino acids; X is an amino acid sequence which comprises the amino acid sequence of SEQ ID NO: 1, or which comprises an amino acid sequence with 8 or less amino acid sequence changes as compared to SEQ ID NO: 1; Y comprises an amino acid sequence of a cell introduction domain; and n is an integer between 1 and 3,
wherein the cell introduction domain of Y comprises an amino acid sequence of the following formula (2):
Y1-L2-Y2-Y3  (2)

wherein Y1 is an amino acid sequence which comprises the amino acid sequence of any one of SEQ ID NOs: 2 to 5, or which comprises an amino acid sequence with 30 or less amino acid sequence changes as compared to any one of SEO ID NOs: 2 to 5; Y2 is an amino acid sequence which comprises the amino acid sequence of any one of SEQ ID NOs: 6 to 9, or which comprises an amino acid sequence with 15 or less amino acid sequence changes as compared to any one of SEQ ID NOs: 6 to 9; L2 is a second linker sequence having 0 to 30 amino acids; Y3 is an amino acid sequence for modification; and either of Y2 and Y3 may be absent,
and wherein said amino acid changes are selected from the group consisting of additions, deletions, and substitutions.

2. The composite polypeptide according to claim 1 , wherein L 1 comprises the amino acid sequence of SEQ ID NO: 14.

3. A trimer protein comprising a composite polypeptide of claim 1 as a monomer protein, wherein the monomer proteins of said trimer protein are identical to or different from one another.

4. The trimer protein according to claim 3 , which includes a parallel β-sheet structure and a helix structure of the parallel β-sheet structure, said parallel β-sheet structure formed by linking X n s and Y 1 s, respectively, in three molecules of the composite polypeptide, which molecules are identical to or different from one another.

5. A hexamer protein formed through association of two molecules of a trimer protein of claim 3 .

6. A component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration, wherein said vaccine comprises the hexamer protein of claim 5 as an active ingredient, and wherein W is an amino acid sequence comprising a part or the entirety of a P domain of a norovirus capsid protein.

7. A method for producing a composite polypeptide associated product, said method comprising:
bringing molecules of a composite polypeptide of claim 1 into contact with one another within an aqueous liquid, to thereby form at least one of a trimer and a hexamer; and
selectively isolating and recovering the trimer, the hexamer, or both.

8. The method according to claim 7 , wherein the method comprises:
culturing, in a liquid culture medium, a transformant into which a nucleic acid fragment encoding the composite polypeptide has been incorporated, to thereby produce molecules of the composite polypeptide through gene expression, wherein said molecules of the composite polypeptide self-associate to form at least one of a trimer and a hexamer; and
selectively isolating and recovering the trimer, the hexamer, or both.

Assignees

• Denka Company Ltd
• Tokyo Inst Tech
• The Kitasato Inst
• Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
• Director General Of Nat Institute Of Infectious Diseases

Inventors

• Ueno Takafumi
• YOSHIKAWA Kengo
• MANO Megumi
• Katayama Kazuhiko
• Miki Motohiro
• Todaka Reiko
• Takahashi Yoshimasa
• Onodera Taishi

Classifications

• A61P31/12

  Antivirals · CPC title

• A61K39/125 Primary

  Picornaviridae, e.g. calicivirus · CPC title

• C12P21/02

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title

• C07K2319/60

  containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP] · CPC title

• C07K14/085

  Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus · CPC title